Elevation Oncology (NASDAQ:ELEV) Coverage Initiated at Piper Sandler

Piper Sandler initiated coverage on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a report issued on Friday morning, MarketBeat reports. The firm issued an overweight rating and a $10.00 target price on the stock. A number of other research firms also recently weighed in on ELEV. JMP Securities reaffirmed a market outperform rating […]

Leave a Reply

Your email address will not be published.

Previous post Head-To-Head Contrast: Savers Value Village (SVV) versus Its Peers
Next post Canadian Imperial Bank of Commerce (TSE:CM) Price Target Raised to C$71.00 at Desjardins